Posted by Michael Wonder on 28 Oct 2024
Astellas provides update on marketing authorisation application for avacincaptad pegol in the European Union
28 October 2024 - Astellas today announced the company's decision to withdraw its marketing authorisation application from the EMA for avacincaptad pegol intravitreal solution, an investigational synthetic aptamer that inhibits the complement C5 protein, for the treatment of geographic atrophy secondary to age-related macular degeneration.
The company's decision to withdraw its application followed interactions with the EMA’s CHMP.
